Ocular Therapeutix Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	55.78	63.72	58.44	51.49	43.52	17.4
Revenue Growth (YoY)	-9.21%	9.03%	13.49%	18.32%	150.08%	311.71%
Cost of Revenue	193.5	133.26	66.34	58	54.49	30.78
Gross Profit	-137.71	-69.54	-7.89	-6.51	-10.97	-13.37
Selling, General & Admin	126.22	103.84	74.49	72.15	67.07	49.47
Operating Expenses	126.22	103.84	74.49	72.15	67.07	49.47
Operating Income	-263.93	-173.38	-82.38	-78.65	-78.04	-62.85
Interest Expense	-12.11	-13.58	-11.34	-7.02	-6.67	-6.77
Interest & Investment Income	15.68	20.28	3.98	0.8	0.03	0.17
Other Non Operating Income (Expenses)	-2.44	-0.48	-5.19	13.84	78.12	-86.19
EBT Excluding Unusual Items	-262.8	-167.16	-94.93	-71.04	-6.55	-155.64
Merger & Restructuring Charges	13.1	1.6	-	-	-	-
Other Unusual Items	-	-27.95	14.19	-	-	-
Pretax Income	-249.67	-193.51	-80.74	-71.04	-6.55	-155.64
Net Income	-249.67	-193.51	-80.74	-71.04	-6.55	-155.64
Net Income to Common	-249.67	-193.51	-80.74	-71.04	-6.55	-155.64
Shares Outstanding (Basic)	174	158	80	77	76	61
Shares Outstanding (Diluted)	174	158	86	83	82	61
Shares Change (YoY)	26.34%	84.90%	3.57%	0.59%	35.24%	34.19%
EPS (Basic)	-1.44	-1.22	-1.01	-0.92	-0.09	-2.56
EPS (Diluted)	-1.44	-1.22	-1.02	-0.97	-0.98	-2.56
Free Cash Flow	-199.44	-135.97	-76.32	-63.32	-66.74	-54.4
Free Cash Flow Per Share	-1.15	-0.86	-0.89	-0.77	-0.81	-0.90
Gross Margin	-246.87%	-109.13%	-13.51%	-12.64%	-25.20%	-76.85%
Operating Margin	-473.14%	-272.08%	-140.96%	-152.74%	-179.31%	-361.13%
Profit Margin	-447.58%	-303.67%	-138.15%	-137.95%	-15.06%	-894.31%
Free Cash Flow Margin	-357.52%	-213.37%	-130.59%	-122.96%	-153.36%	-312.56%
EBITDA	-259.91	-169.6	-79.4	-76.55	-75.62	-60.07
EBITDA Margin	-	-266.14%	-135.86%	-148.65%	-173.74%	-
D&A For EBITDA	4.03	3.79	2.98	2.11	2.42	2.77
EBIT	-263.93	-173.38	-82.38	-78.65	-78.04	-62.85
EBIT Margin	-	-272.08%	-140.96%	-152.74%	-179.31%	-
Revenue as Reported	55.78	63.72	58.44	51.49	43.52	17.4

Source: S&P Global Market Intelligence. Standard template. Financial Sources.